Cover Image
市場調查報告書

裘馨氏肌肉萎縮症的全球市場:2015∼2019年

Global Duchenne Muscular Dystrophy Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 338505
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
裘馨氏肌肉萎縮症的全球市場:2015∼2019年 Global Duchenne Muscular Dystrophy Drugs Market 2015-2019
出版日期: 2015年08月26日 內容資訊: 英文 67 Pages
簡介

裘馨氏肌肉萎縮症是由於Dystrophin基因的變異引起,使Dystrophin陷入產生不足。缺乏Dystrophin的話肌肉功能會變弱,步行困難,危害呼吸系統和心臟最終死亡。預計全球裘馨氏肌肉萎縮症市場2014∼2019年以年複合成長率152.3%擴大。

本報告提供全球裘馨氏肌肉萎縮症市場現狀及未來方案的相關調查、市場規模、收益預測、各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

  • 市場概要
  • 主要供應商的產品

第3章 市場調查方法

第4章 簡介

第5章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 各作用機制市場區隔

  • Exon skipping mechanism
  • Premature stop codon read-through mechanism
  • 其他

第7章 疾病的理解

  • 病因
  • 症狀
  • 生物標記
  • 診斷
  • 分期
  • 來自傳統的管理方法
  • 近幾年的治療方法的發展

第8章 流行病學及成本分析

第9章 各地區市場區隔

第10章 產品研發線

第11章 推動市場的要素

第12章 推動市場的要素的影響

第13章 市場課題

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 市場佔有率分析:2014年
  • 其他值得注意的供應商

第17章 主要供應商分析

  • BioMarin Pharmaceutical
  • Lilly
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics

第18章 附錄

第19章 Technavio的檢驗

圖表

目錄
Product Code: IRTNTR6987

About Duchenne muscular dystrophy

Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death. The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.

Technavio's analysts forecast the global Duchenne muscular dystrophy drugs market to grow at a CAGR of 152.3% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global Duchenne muscular dystrophy drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various off-label and branded drugs and the expected launch of drug candidates intended to be used in the treatment of Duchenne muscular dystrophy.

Based on mechanism of action of the drugs, the market is segmented as follows:

  • Exon skipping mechanism
  • Premature stop codon red through mechanism
  • Others

This report includes a discussion of the market in the following three regions:

  • Americas: the US, Canada, Mexico, and Brazil
  • EMEA: the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio's report, Global Duchenne Muscular Dystrophy Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global Duchenne muscular dystrophy drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • BioMarin Pharmaceutical
  • Eli Lilly
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics

Other Prominent Vendors

  • Acceleron Pharma
  • Akashi Therapeutics
  • Asklepios BioPharmaceuticals
  • Bristol-Myers Squibb
  • Capricor Therapeutics
  • Catabasis Pharmaceuticals
  • Janssen Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Marathon Pharmaceuticals
  • Nippon Shinyaku
  • Nobelpharma
  • Pfizer
  • Summit Therapeutics
  • Taiho Pharmaceutical

Market driver

  • Significant unmet medical need
  • For a full, detailed list, view our report

Market challenge

  • High cost
  • For a full, detailed list, view our report

Market trend

  • Focus on novel targets
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by mechanism of action

  • Exon skipping mechanism
  • Premature stop codon read-through mechanism
  • Others

PART 07: Understanding the disorder

  • Etiology
  • Symptoms
  • Biomarkers
  • Diagnosis
  • Staging
  • Traditional methods of management of Duchenne muscular dystrophy
  • Recent developments in Duchenne muscular dystrophy therapy

PART 08: Duchenne muscular dystrophy: epidemiology and cost analysis

  • Epidemiology
  • Burden associated with Duchenne muscular dystrophy

PART 09: Geographical segmentation

PART 10: Pipeline portfolio

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other and future prominent vendors

PART 17: Key vendor analysis

  • BioMarin Pharmaceutical
  • Lilly
  • PTC Therapeutics
  • Santhera Pharmaceuticals
  • Sarepta Therapeutics

PART 18: Appendix

  • List of abbreviation

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Global Duchenne muscular dystrophy drugs market 2014-2019 ($ millions)
  • Exhibit 02: Five forces analysis
  • Exhibit 03: Heredogram of Duchenne muscular dystrophy
  • Exhibit 04: Biomarkers used in Duchenne muscular dystrophy
  • Exhibit 05: Various approaches to treating Duchenne muscular dystrophy
  • Exhibit 06: Percentage of Duchenne muscular dystrophy patients treated by exon skipping therapy
  • Exhibit 07: Prevalence of nonsense mutation Duchenne muscular dystrophy 2014
  • Exhibit 08: Global Duchenne muscular dystrophy drugs market segmentation by geography 2014
  • Exhibit 09: Duchenne muscular dystrophy: Pipeline portfolio
  • Exhibit 10: Impact of drivers
  • Exhibit 11: Impact of drivers and challenges
  • Exhibit 12: BioMarin Pharmaceutical: Key takeaways
  • Exhibit 13: Lilly: Key takeaways
  • Exhibit 14: PTC Therapeutics: Key takeaways
  • Exhibit 15: Santhera Pharmaceuticals: Key takeaways
  • Exhibit 16: Sarepta Therapeutics: Key takeaways
Back to Top